Literature DB >> 33733487

Microglia-derived galectin-3 in neuroinflammation; a bittersweet ligand?

Reza Rahimian1, Louis-Charles Béland2, Sachiko Sato3, Jasna Kriz4.   

Abstract

Galectins are soluble β-galactoside-binding proteins found in all multicellular organisms. Galectins may act as danger-associated molecular patterns in innate immunity and/or as pattern-recognition receptors that bind to pathogen-associated molecular patterns. Among different galectin family members, galectin-3 has been the focus of studies in neurodegenerative diseases in recent years. This lectin modulates brain innate immune responses, microglia activation patterns in physiological and pathophysiological settings in a context-dependent manner. Galectin-3 is considered as a pivotal tuner of macrophage and microglial activity. Indeed galectin-3 acts as a double edged sword in neuroinflammatory context and this multimodal lectin has diverse roles in physiological and pathophysiological conditions. Better understanding of galectin-3 physiology (its extracellular and intracellular actions) and structure (its C terminus vs. N terminus) is instrumental to design molecules that selectively modulate galectin-3 function toward neuroprotective phenotypes. Several experimental studies using different approaches and methods have demonstrated both protective and deleterious effects of galectin-3 in neuroinflammatory diseases. According to the crucial role of galectin-3 in modulation of innate immune response in brain, it is an attractive target in drug discovery of neurodegenerative diseases. The current insight attempts to provide an updated and balanced discussion on the role of galectin-3 as a complex endogenous immune modulator. This helps to have a better insight into the development of galectin-3 modulators with translational value in different neurological disorders including stroke and neurodegenerative diseases, such as Alzheimer's disease, Huntington's disease and Parkinson's disease.
© 2021 Wiley Periodicals LLC.

Entities:  

Keywords:  IL4 receptor; TREM2; galectin-3; microglia; neuroinflammation

Mesh:

Substances:

Year:  2021        PMID: 33733487     DOI: 10.1002/med.21784

Source DB:  PubMed          Journal:  Med Res Rev        ISSN: 0198-6325            Impact factor:   12.944


  5 in total

Review 1.  Microglial Inflammatory-Metabolic Pathways and Their Potential Therapeutic Implication in Major Depressive Disorder.

Authors:  Reza Rahimian; Claudia Belliveau; Rebecca Chen; Naguib Mechawar
Journal:  Front Psychiatry       Date:  2022-06-16       Impact factor: 5.435

2.  Uninterrupted CAG repeat drives striatum-selective transcriptionopathy and nuclear pathogenesis in human Huntingtin BAC mice.

Authors:  Xiaofeng Gu; Jeffrey Richman; Peter Langfelder; Nan Wang; Shasha Zhang; Monica Bañez-Coronel; Huei-Bin Wang; Lucia Yang; Lalini Ramanathan; Linna Deng; Chang Sin Park; Christopher R Choi; Jeffrey P Cantle; Fuying Gao; Michelle Gray; Giovanni Coppola; Gillian P Bates; Laura P W Ranum; Steve Horvath; Christopher S Colwell; X William Yang
Journal:  Neuron       Date:  2022-02-02       Impact factor: 18.688

3.  Serum Galectin-3 as a Potential Predictive Biomarker Is Associated with Poststroke Cognitive Impairment.

Authors:  Qian Wang; Kai Wang; Yihong Ma; Simin Li; Yuzhen Xu
Journal:  Oxid Med Cell Longev       Date:  2021-12-02       Impact factor: 6.543

Review 4.  Galectin-3 Involvement in Cognitive Processes for New Therapeutic Considerations.

Authors:  Nataša R Mijailović; Katarina Vesic; Dragana Arsenijevic; Maja Milojević-Rakić; Milica M Borovcanin
Journal:  Front Cell Neurosci       Date:  2022-07-05       Impact factor: 6.147

5.  MG-Pe: A Novel Galectin-3 Ligand with Antimelanoma Properties and Adjuvant Effects to Dacarbazine.

Authors:  Stellee M P Biscaia; Cassiano Pires; Francislaine A R Lívero; Daniel L Bellan; Israel Bini; Silvina O Bustos; Renata O Vasconcelos; Alexandra Acco; Marcello Iacomini; Elaine R Carbonero; Martin K Amstalden; Fábio R Kubata; Richard D Cummings; Marcelo Dias-Baruffi; Fernanda F Simas; Carolina C Oliveira; Rilton A Freitas; Célia Regina Cavichiolo Franco; Roger Chammas; Edvaldo S Trindade
Journal:  Int J Mol Sci       Date:  2022-07-11       Impact factor: 6.208

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.